MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases
Woods, V.; Umansky, T.; Russell, S. M.; McGovern, B. L.; Rosales, R.; Rodriguez, M. L.; van Bakel, H.; Sordillo, E. M.; Simon, V.; Garcia-Sastre, A.; White, K. M.; Smith, D. M.; Haders, D.
Show abstract
The death toll and financial stress posed by the recent COVID-19 pandemic have highlighted the pressing need to develop safe and effective, broad-spectrum inhibitors to treat viral infections. To accelerate the antiviral drug discovery process, we developed GALILEO, a computational platform that interfaces with a customizable bioinformatics pipeline with a geometric deep learning algorithm we named ChemPrint for in silico drug screening. Combining these algorithms with a large chemical repositioning library, we discovered MDL-001, which interacts with the Thumb pocket 1 subdomain of multiple single-stranded RNA viruses. For MDL-001, we demonstrate potent in vitro activity against a broad spectrum of pathogenic viruses, and we demonstrate potent in vivo efficacy in a mouse model of SARS-CoV-2 infection. In clinical trials, orally administered MDL-001 has been shown to be safe and well tolerated. These data underline both the effectiveness of the GALILEO platform for drug discovery and the promise of MDL-001 as a novel broad-spectrum antiviral clinical candidate.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Remdesivir Metabolite GS-441524 Efficiently Inhibits SARS-CoV-2 Infection in Mouse Model 97%
- Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 that Exhibits Antiviral Efficacy in SARS-CoV-2 Infected African Green Monkeys 96%
- Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease 95%
Similar papers in this journal
- A hybrid in silico approach reveals novel inhibitors of multiple SARS-CoV-2 variants 94%
- Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles 94%
- An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19 93%
Similar papers in this journal
- Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro 95%
- A repurposed drug screen identifies compounds that inhibit the binding of the COVID-19 spike protein to ACE2 94%
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 94%
Similar papers in this journal
- Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture 95%
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2 94%
- Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.